Paul-Ehrlich-Institut

Go to:

Information on the Use of Cookies

In order to operate and optimise our website, we would like to collect and analyse statistical information completely anonymously. Will you accept the temporary use of statistics cookies?

You can revoke your consent at any time in our privacy policy.

OK

Other Medicinal Products for Human Use

Medicines for which the Paul-Ehrlich-Institut is responsible, but which are not assigned to a particular group of medicines.

Search results 26 to 30 from a total of 30

Name De­scrip­tion Mar­ket­ing Au­tho­ri­sa­tion Hold­er Kind of Vac­cine Li­cense Num­ber Li­cense Date Further Information

Uro-Vaxom

lysierte immunaktive Fraktionen aus ausgewählten Escherichia-coli-Stämmen

Anwendung bei rezidivierenden und chronischen Harnwegsinfektionen

OMEDICAMED Unipessoal Lda

weitere 450a/85 11.12.1987

PharmNet.Bund

Strovac

Inaktivierte Keime spezifizierter Enterobakterien

Anwendung bei wiederkehrenden Harnwegsinfektionen bakterieller Herkunft

Strathmann GmbH & Co. KG

 weitere 16a/84a 12.07.1984

PharmNet.Bund

Broncho-Vaxom 7 mg

lyophilisierte Bakterienlysate

Prophylaxe bei rezidivierenden Atemwegsinfektionen bei Erwachsenen und Jugendlichen ab 12 Jahren

OMEDICAMED Unipessoal Lda

weitere 35a/83 26.09.1983

PharmNet.Bund

Broncho-Vaxom Kinder (3,5 mg Kapseln)

lyophilisierte Bakterienlysate

Prophylaxe bei rezidivierenden Atemwegsinfektionen bei Kindern ab 1 Jahr bis 12 Jahren

OMEDICAMED Unipessoal Lda

weitere 34a/83 26.09.1983

PharmNet.Bund

Gynatren

Inaktivierte Keime spezifizierter Lactobacillus-Stämme

Anwendung bei wiederkehrenden unspezifischen bakteriellen Scheidenentzündungen und Trichomoniasis

Strathmann GmbH & Co. KG

 weitere 52a/82 27.01.1983

PharmNet.Bund

Disclaimer

The list of medicines contains the products that have a valid marketing authorization. It contains no information as to whether the preparations are available on the market.

The information contained in the Federal Gazette, which is the official publication organ of the Paul-Ehrlich-Institut, is legally binding.

As of: PEI announcement No. 519 in BAnz AT 26.07.2024 B6.

Summary of Product Characteristics (SmPCs) and the Package Leaflet (PL)

Where the European Medicines Agency (EMA) offers further information, you will find a link to the EPAR (European public assessment report) in the table.

If user and technical information or public assessment reports are available in PharmNet.Bund, the Federal and State Pharmaceutical Information Portal, these are directly linked to PharmNet.Bund in the table.

Updated: 26.07.2024